Shock wave therapy in cardiology: a commentary

Abstract

The evidences in favor of efficiency of shock-wave in ischemic heart disease therapy are originated mainly from small, uncontrolled observational studies. The experiments have relatively short duration. The shock-wave therapy benefits for ischemic heart disease have been explained by heightened myocardial perfusion and angiogenesis attributed among others to activation of vascular endothelial growth factors of the VEGF group. The role of VEGF in heart diseases and atherosclerosis is ambivalent; along with potential benefit it may contribute to fibrosis. A shock wave induces tissue cavitation and shear stress to membranes. The vulnerability of cardiac muscle cells under conditions of ischemia is increased. Additional damage may contribute to the cell loss. Reported effects of shock-wave treatment may be transient and reactive in their nature. Clinical improvements in humans are caused, at least in part, by the placebo effect. Placebo therapy is beneficial for some patients; however, placebo must be harmless by definition. In conclusion, animal experiments with a longer follow-up are needed prior to the initiation of clinical research with large cohorts of patients. However, some possible late outcomes such as increased vascularization of atherosclerotic plaques and their instability cannot be reliably reproduced in experiments. A promising approach to the evaluation of net harm or benefit could be lifelong animal experiments with comparisons of average life span between test and control groups.

Key words

shock wave therapy, ischemic heart disease, angina pectoris

References

1. Nishida T., Shimokawa H., Oi K., Tatewaki H., Uwatoku T., Abe K., Matsumoto Y., Kajihara N., Eto M., Matsuda T., Yasui H., Takeshita A., Sunagawa K. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-шnduced myocardial dysfunction in pigs in vivo. Circulation. 2004; 110 (19): 3055–3061. doi: 10.1161/01.CIR.0000148849.51177.97

2. Ito Y., Ito K., Shiroto T., Tsuburaya R., Yi G.J., Takeda M., Fukumoto Y., Yasuda S., Shimokawa H. Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo. Coron. Artery Dis. 2010; 21 (5): 304–311. doi: 10.1097/mca.0b013e32833aec62

3. Nazer B., Gerstenfeld E.P., Hata A., Crum L.A., Matula T.J. Cardiovascular applications of therapeutic ultrasound. J. Interv. Card. Electrophysiol. 2014; 39 (3): 287–294. doi: 10.1007/s10840-013-9845-z

4. Uwatoku T., Ito K., Abe K., Oi K., Hizume T., Sunagawa K., Shimokawa H. Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs. Coron. Artery. Dis. 2007; 18 (5): 397–404. doi: 10.1097/MCA.0b013e328089f19b

5. Slikkerveer J., de Boer K., Robbers L.F., van Rossum A.C., Kamp O. Evaluation of extracorporeal shock wave therapy for refractory angina pectoris with quantitative analysis using cardiac magnetic resonance imaging: a short communication. Neth. Heart J. 2016; 24 (5): 319–325. doi: 10.1007/s12471-016-0825-7

6. Ito K., Fukumoto Y., Shimokawa H. Extracorporeal shock wave therapy for ischemic cardiovascular disorders. Am. J. Cardiovasc. Drugs. 2011; 11 (5): 295–302. doi: 10.2165/11592760-000000000-00000

7. Gollmann-Tepeköylü C., Lobenwein D., Theurl M., Primessnig U., Lener D., Kirchmair E., Mathes W., Graber M., Pölzl L., An A., Koziel K., Pechriggl E., Voelkl J., Paulus P., Schaden W., Grimm M., Kirchmair R., Holfeld J. Shock wave therapy improves cardiac function in a model of chronic ischemic heart failure: Evidence for a mechanism involving vegf signaling and the extracellular matrix. J. Am. Heart Assoc. 2018; 7 (20): e010025. doi: 10.1161/JAHA.118.010025

8. Čelutkienė J., Burneikaitė G., Shkolnik E., Jakutis G., Vajauskas D., Čerlinskaitė K., Zuozienė G., Petrauskienė B., Puronaitė R., Komiagienė R., Butkuvienė I., Steponėnienė R., Misiūra J., Laucevičius A. The effect of cardiac shock wave therapy on myocardial function and perfusion in the randomized, triple-blind, sham-procedure controlled study. Cardiovasc. Ultrasound. 2019; 17 (1): 13. doi: 10.1186/s12947-019-0163-1

9. Burneikaitė G., Shkolnik E., Čelutkienė J., Zuozienė G., Butkuvienė I., Petrauskienė B., Šerpytis P., Laucevičius A., Lerman A. Cardiac shock-wave therapy in the treatment of coronary artery disease: systematic review and meta-analysis. Cardiovasc. Ultrasound. 2017; 15 (1): 11. doi: 10.1186/s12947-017-0102-y

10. Shkolnik E., Burneikaite G., Celutkiene J., Scherbak M., Zuoziene G., Petrauskiene B., Trush E., Laucevicius A., Vasyuk Y. Efficacy of cardiac shock wave therapy in patients with stable angina: The design of randomized, triple blind, sham-procedure controlled study. Anatol. J. Cardiol. 2018; 19 (2): 100–109. doi: 10.14744/AnatolJCardiol.2017.8023

11. Wang J., Zhou C., Liu L., Pan X., Guo T. Clinical effect of cardiac shock wave therapy on patients with ischaemic heart disease: a systematic review and meta-analysis. Eur. J. Clin. Invest. 2015; 45 (12): 1270–1285. doi: 10.1111/eci.12546

12. Jargin S.V. Shock wave therapy of ischemic heart disease in the light of general pathology. Int. J. Cardiol. 2010; 144 (1): 116–117. doi: 10.1016/j.ijcard.2008.12.198

13. Iargin S.V. Shock-wave therapy of angina pectoris from positions of general pathology. Kardiologiya = Cardiology. 2010; 50(6): 75–76. [In Russian].

14. Ignarro L.J. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension. 1990; 16 (5): 477–483. doi: 10.1161/01.hyp.16.5.477

15. Tsutsumi Y., Losordo D.W. Double face of VEGF. Circulation. 2005; 112 (9): 1248–1250. doi: 10.1161/CIRCULATIONAHA.105.566166

16. Laakkonen J.P., Lähteenvuo J., Jauhiainen S., Heikura T., Ylä-Herttuala S. Beyond endothelial cells: Vascular endothelial growth factors in heart, vascular anomalies and placenta. Vascul. Pharmacol. 2019; 112: 91–101. doi: 10.1016/j.vph.2018.10.005

17. Chen F., Eriksson P., Kimura T., Herzfeld I., Valen G. Apoptosis and angiogenesis are induced in the unstable coronary atherosclerotic plaque. Coron. Artery Dis. 2005; 16 (3): 191–197. doi: 10.1097/00019501-200505000-00009

18. Azimi-Nezhad M. Vascular endothelial growth factor from embryonic status to cardiovascular pathology. Rep. Biochem. Mol. Biol. 2014; 2 (2): 59–69.

19. Heeschen C., Dimmeler S., Hamm C.W., Boersma E., Zeiher A.M., Simoons M.L.; on Behalf of the CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003; 107 (4): 524–530. doi: 10.1161/01.cir.0000048183.37648.1a

20. Testa U., Pannitteri G., Condorelli G.L. Vascular endothelial growth factors in cardiovascular medicine. J. Cardiovasc. Med. 2008; 9 (12): 1190–1221. doi: 10.2459/JCM.0b013e3283117d37

21. Gabrusenko S.A., Malakhov V.V., Shitov V.N., Sanakova A.N., Sergienko V.B., Masenko V.P., Kukharchuk V.V. An experience of the use of a curative method of cardiac shock wave therapy in patients with ischemic heart disease. Kardiologiya = Cardiology. 2013; (5): 20–26. [In Russian].

22. Baroldi G. Myocardial cell death, including ischemic heart disease and its complications. In: Cardiovascular pathology. Eds. M.D. Silver, A.I. Gotlieb, F.J. Schoen. New York: Churchill Livingstone, 2001; 198–255.

23. Zelenin GB. Shock wave therapy: a new perspective non-invasive treatment of ischemic heart disease. Zdravookhranenie = Healthcare. 2007; (9): 172–178. [In Russian].

24. Garilevich B.A., Semenov A.A., Gurevich K.G., Nagornev S.N., Radchenko S.N., Puzyreva G.A. Shock-wave therapy: status update on the problem and possibilities of application in clinical practice. Kurskiy nauchno-prakticheskij vestnik «Chelovek i ego zdorov’e» = Kursk Scientific and Practical Bulletin “Man and His Health”. 2017; (3): 11–18. doi: 10.21626/vestnik/2017-3/02

25. Moosavi-Nejad S.F., Hosseini S.H., Satoh M., Takayama K. Shock wave induced cytoskeletal and morphological deformations in a human renal carcinoma cell line. Cancer Sci. 2006; 97: 296–304. doi: 10.1111/j.1349-7006.2006.00172.x

26. Mayer R., Schenk E., Child S., Norton S., Cox C., Hartman C., Cox C., Carstensen E. Pressure threshold for shock wave induced renal hemorrhage. J. Urol. 1990; 144: 1505–1509. doi: 10.1016/s0022-5347(17)39787-2

27. Delius M., Enders G., Heine G., Stark J., Remberger K., Brendel W. Biological effects of shock waves: lung hemorrhage by shock waves in dogs - pressure dependence. Ultrasound Med. Biol. 1987; 13: 61–67. doi: 10.1016/0301-5629(87)90075-5

28. Roessler W., Steinbach P., Seitz R., Hofstaedter F., Wieland W.F. Mechanisms of shockwave action in the human kidney. J. Endourol. 1995; 9 (6): 443–448. doi: 10.1089/end.1995.9.443

29. Holfeld J., Zimpfer D., Schaden W., Grimm M. Reply to Sergej V. Jargin: shock wave therapy of ischemic heart disease in the light of general pathology. Int. J. Cardiol. 2010; 145 (2): 240–241. doi: 10.1016/j.ijcard.2009.08.025

30. Shchegol’kov A.M., Yudin V.E., Budko A.A., Sychev V.V., Korshikova N.V., Pushkarev E.P. Hock-wave therapy in the complex treatment and rehabilitation of patients with coronary heart disease with refractory angina. Vestnik vosstanovitel'noy meditsiny = Bulletin of rehabilitation medicine. 2014; (6): 69–75. [In Russian].

31. Kaller M., Faber L., Bogunovic N., Horstkotte D., Burchert W., Lindner O. Cardiac shock wave therapy and myocardial perfusion in severe coronary artery disease. Clin. Res. Cardiol. 2015; 104 (10): 843–849. doi: 10.1007/s00392-015-0853-0

32. Liu B., Zhang Y., Jia N., Lan M., Du L., Zhao D., He Q. Study of the safety of extracorporeal cardiac shock wave therapy: observation of the ultrastructures in myocardial cells by transmission electron microscopy. J. Cardiovasc. Pharmacol. Ther. 2018; 23 (1): 79–88. doi: 10.1177/1074248417725877

33. Rausch I., Füchsel F.G., Kuderer C., Hentschel M., Beyer T. Radiation exposure levels of routine SPECT/CT imaging protocols. Eur. J. Radiol. 2016; 85 (9): 1627–1636. doi: 10.1016/j.ejrad.2016.06.022

34. Khattab A.A., Brodersen B., Schuermann-Kuchenbrandt D., Beurich H., Tölg R., Geist V., Schäfer T., Richardt G. Extracorporeal cardiac shock wave therapy: first experience in the everyday practice for treatment of chronic refractory angina pectoris. Int. J. Cardiol. 2007; 121 (1): 84–85. doi: 10.1016/j.ijcard.2006.08.030

35. Weihrauch T.R. Placebo treatment is effective differently in different diseases - but is it also harmless? A brief synopsis. Sci. Eng. Ethics. 2004; 10 (1): 151–155. doi: 10.1007/s11948-004-0072-y

36. Gutersohn A., Caspari Т., Erbel R. New non-invasive therapeutic opportunities in the treatment of «refractory» angina and myocardial ischemia: 5 years of clinical experience. ESC. 2004; 27 (11): 1341-1381.

37. Jargin S.V. Hormetic use of stress in gerontological interventions requires a cautious approach. Biogerontology. 2016; 17 (2): 417–420. doi: 10.1007/s10522-015-9630-8

38. Jargin S.V. On the biological effects of radiofrequency electromagnetic fields. Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal. 2019; 39 (5): 52–61. [In Russian]. doi: 10.15372/SSMJ20190506

39. Jargin S.V. Scientific papers and patents on substances with unproven effects. Part 2. Recent Pat. Drug Deliv. Formul. 2019; 13 (3): 160–173. doi: 10.2174/1872211313666190819124752

40. Holfeld J., Zimpfer D., Albrecht-Schgoer K., Stojadinovic A., Paulus P., Dumfarth J., Thomas A., Lobenwein D., Tepeköylü C., Rosenhek R., Schaden W., Kirchmair R., Aharinejad S., Grimm M. Epicardial shock-wave therapy improves ventricular function in a porcine model of ischaemic heart disease. J. Tissue Eng. Regen. Med. 2016; 10 (12): 1057–1064. doi: 10.1002/term.1890

About Authors (Correspondence):

Jargin S.V., e-mail: sjargin@mail.ru

Full Text

snmzh_3-2020_yargin.pdf

Received: 30/06/2020

Accepted: 30/06/2020